INMB PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

INMB ▼ -0.70% at T+20d

SHORT call ✓ call won +0.70% · α vs SPY +5.67% · entry $1.43 → $1.42

Next anchor: T+60d in 6w

Currently $1.24 · +13.29% from $1.43 entry (call sign-flipped)

Entry anchored
Apr 29, 03:59 PM ET
via Databento tick

T+1d

+5.59%

call -5.59% · α -5.37%

$1.51

settled 6w ago

T+5d

+6.29%

call -6.29% · α -4.57%

$1.52

settled 5w ago

T+20d

-0.70%

call +0.70% · α +5.67%

$1.42

settled 15d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

INmune Bio reported Q4 2025 EPS of -$0.20, missing the consensus estimate of -$0.18 by 11.1%. The press release announces a Q1 2026 earnings call but provides no financial results or guidance for that period, leaving the market without a clear catalyst.

Actionable Insight

The EPS miss and lack of Q1 2026 financials or guidance create near-term uncertainty. Monitor the May 7 call for pipeline updates (XPro, INKmune, CORDStrom) and any cash runway commentary. The stock may remain under pressure until a catalyst emerges.

Key Facts

Q4 2025 EPS of -$0.20 missed consensus of -$0.18 by 11.1%.
No revenue reported for Q4 2025; consensus expected $0.
Press release only announces Q1 2026 earnings call date (May 7, 2026) with no financial data or guidance.
Company is a clinical-stage biotech with no approved products, relying on pipeline progress.
Market cap is $35M, and analyst consensus is 90% bullish, but the EPS miss is a negative signal.

Financial Impact

EPS miss of 11.1% on a small base; no revenue or guidance provided.

eps

Risk Factors

No approved products or revenue stream; reliance on clinical trial outcomes.
EPS miss could erode investor confidence in a low-cap stock.
Lack of guidance increases uncertainty around cash burn and timeline to milestones.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3284769

6 reports for INMB

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for INMB — sortable, filterable
	Type				Now
Jun 2, 2026 10d ago	8-K BULLISH ★ 7/10	$1.32 $1.35	▲ +2.27%	▲ +1.87%	$1.24 (−6.06%)
May 7, 2026 5w ago	Press Release MIXED ★ 4/10	$1.43 $1.35	▼ −5.59%	▼ −5.83%	$1.24 (−13.29%)
May 5, 2026 5w ago	8-K NEUTRAL ★ 4/10	$1.52 $1.43	▼ −5.92%	▼ −5.59%	$1.24 (−18.42%)
Apr 30, 2026 6w ago	Press Release BEARISH ★ 6/10	$1.43 $1.51	▼ −5.59%	▼ −5.37%	$1.24 (+13.29%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 6/10	$1.13 $1.23	▲ +8.85%	▲ +8.10%	$1.24 (+9.73%)
Mar 19, 2026 12w ago	Press Release BULLISH ★ 7/10	$1.22 $1.17	▼ −4.10%	▼ −2.36%	$1.24 (+1.64%)

US Market Status

Market Closed — Opens Mon (49h 13m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access